Inter-ethnic differences in drug handling and frequencies of pharmacogenetic variants are increasingly being characterized. In this study, we systematically assessed the feasibility of inferring ethnic trends in chemotherapy outcomes from inter-ethnic differences in pharmacogenetic variant frequencies. Frequencies of 51 variants and chemotherapy outcomes of East Asian and Caucasian colorectal cancer patients on standard chemotherapy regimens were summarized by meta-analyses, and variant frequencies were validated by MassARRAY analysis. Inferences of relative chemotherapy outcomes were made by considering minor allele function and population differences in their frequency. Significant population differences in genotype distributions were observed for 13/23 (60%) and 27/35 (77%) variants in the meta-analyses and validation series, respectively. Across chemotherapy regimens, East Asians had lower rates of grade 3/4 toxicity for diarrhea and stomatitis/mucositis than Caucasians, which was correctly inferred from 13/18 (72%, P ¼ 0.018) informative genetic variants. With appropriate variant selection, inferring relative population toxicity rates from population genotype differences may be relevant.
INTRODUCTION
Traditionally, chemotherapy regimens have been developed in the US and Europe on primarily Caucasian populations and subsequently adopted for use in other populations. However, interethnic variability in chemotherapy drug handling has been a common anecdotal observation, with systematic evidence beginning to emerge. 1--4 At the same time, it has become increasingly evident that population differences in drug response may be related to interethnic differences in the frequencies of relevant pharmacogenetic variants. A prominent example is the higher frequencies of response to EGFR inhibitors of East Asians to Caucasians that have been linked to the higher frequencies of sensitizing somatic EGFR mutations in East Asians. 2 Another example is the lower average warfarin requirements of Chinese to Indians linked to the higher frequency of the VKORC1 H1 haplotype in Chinese. 5 Indeed, the influence of both ethnicity and genetic variation on drug handling has also been recognized by the US Food and Drug Administration in their relabelling of a number of drugs. 6, 7 The sequencing of the human genome, along with the HapMap and 1000 Genomes projects have characterized the genetic variability between different ethnic populations, including pharmacogentic variants. 8, 9 This, together with the emerging evidence described above, leads to the hypothesis that inter-ethnic differences in the frequency of pharmacogenetic variants could be useful in estimating population differences in chemotherapy outcomes. However, systematic information on both inter-ethnic patient pharmacogenetic variant frequencies and chemotherapy outcomes to test this hypothesis is limited.
In this study, a meta-analysis approach was used to characterize relevant pharmacogenetic variant frequencies and chemotherapy outcomes in East Asian and Caucasian colorectal cancer (CRC) patients, and explore their possible correlation.
MATERIALS AND METHODS

Characterization of pharmacogenetic variant frequencies
Pharmacogenetic variants considered in this study were obtained from a review of variants linked to 5-FU-, irinotecan-or oxaliplatin-based chemotherapy outcomes. 10 Additional variants for capecitabine chemotherapy were also identified. All variants considered are listed in Supplementary File S1. Studies reporting on variant frequencies in CRC patients were identified from PubMed. The search terms and inclusion/ exclusion criteria can be found in Supplementary File S1, whereas a flowchart outlining the filtering process is available as Supplementary Figure S1 . Information annotated included first author, year of publication, region of study population, number of cases analyzed and variant frequencies. Studies from Australia, Europe, North America and multinational studies were categorized as 'Caucasian'. Studies originating from China, Korea, Japan, Taiwan and Hong Kong were classified as 'East Asian'. Where provided, data from East Asian and Caucasian subgroups were extracted within studies. Data from other populations (non-East Asian/ Caucasian) were also recorded but not analyzed owing to the small number of studies (Supplementary File S2).
Genotyping of East Asian and Caucasian CRC patients
Following institutional review and approval of study protocols, normal colonic tissue DNA was obtained from 246 East Asian CRC patients (Kanazawa University Hospital, Kanazawa, Japan) and 277 Caucasian CRC patients (St John of God Hospital, Perth, Western Australia, Australia). Extraction of DNA was performed using standard phenol--chloroform methods. Genotyping was performed using the iPLEX assay on the MassARRAY system (Sequenom, San Diego, CA, USA). For variants previously investigated in more than one study and where genotyping by MassARRAY was not possible, alternative methods were employed. 11--14 PHASE version 2.1.1 software was used to construct haplotypes. 15 Data from assays with genotypes interpretable in o50% of cases and/or with genotype distributions differing (Po0.001) from those reported previously were excluded from the analysis. Genotyping methods, primer sequences, reference single nucleotide polymorphism identification number (RSIDs) and reasons for exclusion are reported in Supplementary File S3.
Characterization of CRC patient outcomes from clinical trials
Relevant trials were identified from CENTRAL (Cochrane Central Register of Controlled Trials). Trials with at least one arm consisting of fluorouracil (5FU) and leucovorin (denoted by F þ L), 5FU, leucovorin and irinotecan (denoted by FLI, includes FOLFIRI), or 5FU, leucovorin and oxaliplatin (denoted by FLO, includes FOLFOX) as first-line treatments were selected. Additional arms of FLI and FLO were also retrieved from PubMed. The search terms and flowchart outlining the inclusion strategy are available in Supplementary File S1 and Supplementary Figure S2 , respectively.
Studies were limited to Phase II and III clinical trials conducted on East Asians and/or Caucasians. The same classification for ethnicity, as mentioned above, was applied. All forms of administration were considered, including different schedules and dosages. Trials of both early stage and metastatic CRC patients were included. Studies of rectal cancer patients who received prior or concurrent radiotherapy were excluded. Additional trials were identified through references cited in retrieved articles.
Annotated data included first author, year of publication, ethnicity, regimen, number of subjects, toxicity rates, clinical response rates and median overall survival (OS) time (Supplementary File S4). For toxicity rates, the frequency of grade 3/4 toxicity, defined using WHO/NCI criteria, was recorded. Information on diarrhea, stomatitis/mucositis, nausea/vomiting and hand--foot syndrome was annotated from arms containing fluoropyrimidines (FPs). Neutropenia, febrile neutropenia, leukopenia, thrombocytopenia and anemia were recorded from FLI and FLO arms, and neuropathy for FLO arms. Data on response rates according to RECIST criteria, and median OS was analyzed from trials of advanced patients only. observed for 27/35 (77%) variants (Supplementary File S5). Ten of 13 variants found to significantly differ in genotype distribution in the meta-analysis were validated to have significant differences in these cases. The exceptions were the frequencies of GSTM1 deletion (P ¼ 0.061), MTHFR A1298C (P ¼ 0.002) and MTHFR C677T (excluded from analysis).
Meta-analysis of CRC patient outcomes in clinical trials Table 1 summarizes the grade 3/4 toxicity and response rates and median OS of East Asian and Caucasian CRC patients by chemotherapy regimen (see Supplementary File S4 for detailed information). For F þ L treatment, toxicity rates were significantly lower in East Asians for all symptoms (diarrhea, P ¼ 0.001; stomatitis/mucositis, P ¼ 0.032; nausea/vomiting, P ¼ 0.015) except hand--foot syndrome. For FLI East Asians had a significantly lower rate of diarrhea (Po0.001), whereas for FLO toxicity rates for Asians were significantly lower for diarrhea (Po0.001) and for stomatitis/mucositis (P ¼ 0.037). There was no significant difference in response rates and median OS between East Asians and Caucasians.
Data heterogeneity was moderate to high for each of the rates/ medians reported for each chemotherapy regimen when East Asian and Caucasian studies were considered together, with publication bias being significant (Po0.1) in 8/29 (28%) eligible analyses. Heterogeneity was low among East Asian studies but was moderate to high among Caucasian studies.
Meta-regression of grade 3/4 toxicity rates in CRC patients on F þ L treatment To assess the contribution of other factors known to influence chemotherapy-related outcomes on the observed inter-ethnic differences, meta-regression analysis was performed. With data available from the largest number of arms, the incidence of grade 3/4 toxicities (diarrhea, stomatitis/mucositis and nausea/vomiting) in CRC patients on F þ L regimen was examined. Ethnicity, setting (adjuvant versus advanced/metastatic), mode of administration (bolus versus continuous infusion), dosage of 5FU and dosage of leucovorin were considered. East Asian ethnicity remained significantly associated (Po0.001) with lower toxicity rates for all the three toxicities ( Table 2) .
Correlation of inferred and observed chemotherapy outcomes Table 3 displays the relative toxicity rates from 5-FU, irinotecan and oxaliplatin treatment inferred for East Asians from inter-ethnic differences in pharmacogenetic variant frequencies. Relative toxicity rates were used as an end point, as lower toxicity rates for East Asians were the only significantly different outcome observed in the clinical trial meta-analyses (Table 1) . Inferences were made by first annotating the reported effects of minor alleles on protein function. Knowledge of the role of the proteins in drug pharmacology was then used to project the effect of altered protein function on toxicity rates. Inferences on relative toxicity rates for East Asians were then made by combining the projected relative toxicity rates of minor alleles with their relative frequencies in East Asians in the validation series. If the allele frequencies for a specific variant were not significantly different between East Asians and Caucasians, nonsignificant trends were inferred and denoted with 'NS'.
For 10/30 (33%) variants examined, an inference could not be made, as effects on protein function or drug pharmacology were unknown or unclear. For 2/30 (7%) variants, previous reports indicated a lack of functional effect. Of the remaining 18 variants, lower toxicity rates were inferred for East Asians from 9 (50%) (P ¼ 0.075, compared with random chance), higher toxicity rates from 5 (28%) and no difference from 4 (22%). When nonsignificant trends were also considered, lower toxicity rates were inferred from 13/18 (72%) variants (P ¼ 0.018) and higher toxicity rates from 5/18 (28%) variants.
DISCUSSION
Emerging evidence in recent years has highlighted populationbased differences in chemotherapy outcomes, with most studies focusing on African-Americans and Caucasians.
1--4,25--37 In trialbased analyses, significantly lower rates of toxicity to XELOX and FULV were also observed in CRC patients from East Asia compared with the rest of the world, 1 and to UFT/LV in Asian-American compared with Caucasian-American patients in California. 3 At the same time, the association of pharmacogenetic variants with adverse events and response has also been demonstrated in individual trial-based studies. 14,38--42 In 2009, Gandara et al. Variant involved for both irinotecan and oxaliplatin.
Inferring treatment outcomes from pharmacogenetics M Loh et al reported that CYP3A4*1B and ERCC2 K751Q were associated with patient outcomes in a US--Japanese common-arm analysis of paclitaxel and carboplatin of lung cancer patients, and these variants differed in frequencies between the two populations. In this study, a meta-analysis approach was undertaken to gain a wider perspective of whether links between inter-ethnic differences in pharmacogenetic variant frequencies and chemotherapy-related outcomes could be found through summary of published data on East Asian and Caucasian variant frequencies and clinical trial outcomes in CRC. The meta-analyses of variant frequencies revealed significant inter-ethnic differences in the distribution of 13/23 (60%) variants between East Asians and Caucasians. Laboratory genotyping, performed to eliminate interlaboratory and inter-assay variability on determining variant frequencies, revealed an even higher frequency of inter-ethnic difference (77%), including 10/13 variants that were different in the meta-analyses. Although genotype distributions in healthy subjects are available from public databases, 8 DNA from CRC patients was analyzed here as some variants might be riskassociated. 43, 44 Normal tissue was analyzed to avoid the effects of allelic instability on genotyping in tumor DNA. 45 Indeed, for variants where data were available from both HapMap and our validation series, significant differences were detected for almost half of them (data not shown). The laboratory analysis is also useful in providing information on the frequency of 14 variants for which distributions were previously lacking in at least one population.
The meta-analyses of clinical trial data provided evidence that East Asians differ in their chemotherapy outcomes to Caucasians, experiencing generally lower rates of diarrhea and stomatitis/ mucositis (Table 1 ). These lower rates of toxicity were observed in the meta-analyses across different regimens and are also consistent with previous trial-based reports, 1, 3 supporting the reproducibility and robustness of the associations. The commonality of 5-FU in these studies suggest that it could be a major factor in the observed inter-ethnic differences. However, diarrhea and stomatitis/mucositis have also been linked to single-agent treatment with irinotecan and oxaliplatin, 46 thus making it difficult to exclude these drugs as contributing factors to toxicity.
For all the three regimens examined, the RRs observed for East Asians were consistently lower and the median OS consistently higher than for Caucasians. Although these differences did not reach significance (Table 1) , this suggests that East Asians could possibly be underdosed. In support of this, significantly higher gastrointestinal toxicity was observed for the Japanese-developed S-1 fluoropyrimidine in Caucasians relative to East Asians. 47 The ability of East Asians to tolerate higher doses of CRC chemotherapy regimens and to gain benefit from these is an interesting line for further investigation, although alternative rationales such as diet and cultural differences in reporting of toxicities should also be considered. 48, 49 Another possible reason for the lower OS of Caucasians could be the greater proportion of dose reductions or delays of chemotherapy resulting from their higher toxicity rates. The higher median OS for East Asians is also consistent with recent observations from meta-analyses, registry surveys and individual patient data from clinical trials in various cancer types such as lung and pancreatic cancer, 36, 37 providing some early evidence that these trends may be independent of treatment interactions, and more likely related to the higher proportion of favorable tumor subtypes in Asians.
A major goal of this study was to correlate chemotherapy outcomes inferred from population differences in pharmacogenetic variant frequencies with the outcomes observed from meta-analyses of clinical trials. This was not straightforward, however, owing to the varying chemotherapy outcomes reported and the different outcomes inferred for the numerous variants and drugs examined (Table 3 ). The inference of lower toxicity rates in East Asians was assessed, as it was the only significantly different chemotherapy outcome observed in this study (Table 1) . A lower toxicity rate in East Asians was inferred by half of the variants examined (Table 3) , increasing to 72% of variants if nonsignificant trends were also considered. Although not completely concordant, the proportion of variants with the correct inference of lower toxicity in East Asians was nonetheless significantly higher than that of chance, supporting the contention that population differences in chemotherapy outcomes could be inferred from differences in pharmacogenetic variant frequencies.
The absence of complete concordance between observed and inferred chemotherapy outcomes according to pharmacogenetic variants is not unexpected. To maximize study objectivity, we assessed all gene variants linked to fluoropyrimidine, irinotecan and oxaliplatin treatments, and considered them equally. However, it is likely, the variants are not equivalent in their influence on chemotherapy outcomes. For some variants, such as TYMS 2R/ 3R and UGT1A1*28, the strength of associations with chemotherapy outcomes are supported by meta-analyses or large clinical studies. 10 However, the associations for many other variants are supported by only a few studies, studies of small sample size and/ or inconsistent reports. 10, 14, 50 Moreover, the inferences made here were based on reported variant in-vitro of the activities, but these are not always consistent with clinical observations. 10,50 SNP--SNP interactions may exist in-vivo, 51, 52 and compensational effect may also exist between different variants, such as that of UGT1A1*28 and UGT1A1*6, which are known to be inversely correlated in their frequencies in East Asians and Caucasians. 53 Some variants show varying clinical associations according to ethnicity, presumably due to modifiying genes or environmental factors. 54, 55 Other reports link certain variants to specific symptoms only. 10 The development of objective means to evaluate the influence of genetic variants and to link them to specific clinical outcomes would refine the ability to infer population differences in chemotherapy outcomes.
The differences in variant frequency and chemotherapy outcomes reported here were evaluated through retrospective meta-analyses of studies that examined different populations and used different drug scheduling and doses. Significant data heterogeneity and publication bias was observed in many of the meta-analyses. Nonetheless, data from the meta-regression on F þ L arms indicated that East Asian ethnicity remained a significant factor in the lower toxicity observed in East Asian CRC patients despite the addition of information on other wellestablished factors (Table 2) . Statistical limitations are also inherent in the calculation of survival differences from the median survival times of different arms of unrelated trials, rather than the use of hazard ratios. Nevertheless, given the paucity of multiethnic trials, the incomplete reporting of hazard ratios and the lack of individual patient data from historical studies, this was the only feasible means of assessing survival differences.
In conclusion, comprehensive meta-analyses and assessment of genotype frequencies in a single laboratory confirmed that East Asian and Caucasian CRC patients differ significantly in the frequency of many pharmacogenetic variants and in related chemotherapy outcomes. The results provided evidence suggesting that inter-ethnic differences in the frequency of pharmacogenetic variants could be possibly used to predict differences in chemotherapy outcomes, although the fact that the source data was not fully controlled suggests the findings should only be considered exploratory and hypothesis-generating. The emergence of personalized medicine emphasizes the improvements that can be obtained in treatment outcomes by linking single molecular phenotypes to drug pharmacology. 2 However, the relevant molecular phenotypes are still not known for the majority of drugs and regimens that are used in pharmacogenetically diverse populations. The results of this study suggest that a better understanding of pharmacogenetic diversity could help to optimize the use of new and current drugs in different populations. Much work remains to be done, especially in the form of international collaborations, to demonstrate the validity of pharmacogenetically-based inferences in a prospective fashion, as well as in the selection and weighing of relevant pharmacogenetic variants.
